Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Research & Development (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Research & Development data on record, last reported at $587279.0 in Q3 2025.

  • For Q3 2025, Research & Development fell 27.66% year-over-year to $587279.0; the TTM value through Sep 2025 reached $1.3 million, down 56.41%, while the annual FY2024 figure was $2.3 million, 65.04% down from the prior year.
  • Research & Development reached $587279.0 in Q3 2025 per COEP's latest filing, up from $290309.0 in the prior quarter.
  • Across five years, Research & Development topped out at $5.1 million in Q3 2023 and bottomed at $20887.0 in Q3 2022.
  • Average Research & Development over 4 years is $832077.1, with a median of $432723.0 recorded in 2023.
  • Peak YoY movement for Research & Development: surged 24187.54% in 2023, then tumbled 88.85% in 2025.
  • A 4-year view of Research & Development shows it stood at $20887.0 in 2022, then skyrocketed by 4751.57% to $1.0 million in 2023, then tumbled by 66.07% to $343878.0 in 2024, then skyrocketed by 70.78% to $587279.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $587279.0 in Q3 2025, $290309.0 in Q2 2025, and $86659.0 in Q1 2025.